Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement Regarding SCD Patients during the time of “Reopening” the U.S. Economy
May 14, 2020—On Thursday April 16, 2020, the U.S. Coronavirus Taskforce provided recommendations on reopening the economy, giving states specific metrics, policies, and benchmarks regarding case load, hospital preparedness and testing capability with the goal of reopening on May 1. In order to proceed through the entire process, states must complete a two-week pre-phase, and then complete a two-week gating period with no evidence of rebound infections between each of the phases.
During the first two phases, the taskforce recommended that all vulnerable individuals remain at home and that everyone should work from home if they are able to do so. It also concluded that employers should make special accommodations for vulnerable individuals at work if working from home is not possible. During the last phase, vulnerable individuals could resume working normally, with physical distancing while in public places.
It is the position of the Medical and Research Advisory Committee (MARAC) of the Sickle Cell Disease Association of America that patients with sickle cell disease are considered vulnerable individuals based on American Society of Hematology (ASH) COVID19 guidelines.
+myBinderRelated Content
-
National Briefing with CDC: COVID-19 and the Chronic Disease CommunityApril 29th, 2020 from 2PM – 3PM EDT A...
-
Why I Will Be Getting the COVID-19 VaccineOn Nov. 9, Pfizer and BioNTech announced...
-
MARAC Advisory Statement: COVID-19 VaccinesNews is evolving rapidly about COVID-19 ...
-
COVID-19, Sickle Cell Disease, and a Critical NeedWe are facing a global pandemic as cases...
-
You Should Get a COVID-19 Vaccine – Portuguesehttps://www.youtube.com/watch?v=t8UywR9x...
-
Sickle Cell Disease & COVID-19 – Cayenne Wellness Center and Children’s FoundationWednesday, May 27, 2020 from 4:00pm - 6:...
-
NORD/EURORDIS-Rare Diseases Europe Joint Statement on COVID-19 and Orphan Drug LegislationThe National Organization for Rare Disor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.